Patients with type 2 diabetes who use GLP-1 receptor agonists have a significantly lower risk for lung cancer than those who ...

CVOT, notable for comparing the two drugs, tirzepatide showed significantly greater improvements in major kidney outcomes vs dulaglutide.

Shares of Amgen are up nearly 26% this year and have soared 11% just over the past week.

WASHINGTON -- Treatment with the investigational GLP-1/glucagon dual receptor agonist pemvidutide led to resolution of ...

Significant improvements observed in secondary endpoints, including reductions in liver fat, inflammation and biomarkers of fibrosis GAITHERSBURG, Md., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc ...

A multicenter team including Endeavor Health and Eli Lilly found that once-weekly eloralintide produced dose-dependent weight ...

The bidding war between Pfizer ( PFE) and Novo Nordisk ( NVO) over obesity drug developer Metsera ( MTSR) finally ended over ...

In a small, short duration trial (12 weeks), a new medication called DR10624 reduced triglyceride levels in most patients with severe hypertriglyceridemia by more than 60%, according to a preliminary ...

Tirzepatide's dual mechanism targets GIP and GLP-1, so it provides strong cardiovascular benefits, said Stephen Nicholls, ...

AnaptysBio has abandoned plans to develop rosnilimab for ulcerative colitis (UC) after the PD-1 agonist flunked a phase 2 study.

SEP-479 Selected as Next-Generation Oral PTH1R Agonist Development CandidateSEP-631 (MRGPRX2 NAM) Phase 1 Clinical Trial in Healthy Volunteers ...

MNA-001 has best-in-class potential based on preclinical data demonstrating ability to significantly reduce neurotoxic amyloid burden and reprogram microglia to protective states Phase 1 study ...